These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 8194166)
21. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. Anderson CP; Seeger RC; Satake N; Monforte-Munoz HL; Keshelava N; Bailey HH; Reynolds CP J Pediatr Hematol Oncol; 2001 Nov; 23(8):500-5. PubMed ID: 11878777 [TBL] [Abstract][Full Text] [Related]
22. Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents. Yen L; Woo A; Christopoulopoulos G; Batist G; Panasci L; Roy R; Mitra S; Alaoui-Jamali MA Mutat Res; 1995 Nov; 337(3):179-89. PubMed ID: 7491121 [TBL] [Abstract][Full Text] [Related]
23. The role of glutathione in resistance to cisplatin in a human small cell lung cancer cell line. Meijer C; Mulder NH; Hospers GA; Uges DR; de Vries EG Br J Cancer; 1990 Jul; 62(1):72-7. PubMed ID: 2390486 [TBL] [Abstract][Full Text] [Related]
24. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Anderson CP; Reynolds CP Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530 [TBL] [Abstract][Full Text] [Related]
25. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of DNA repair and the enhancement of cytotoxicity of alkylating agents. Frankfurt OS Int J Cancer; 1991 Jul; 48(6):916-23. PubMed ID: 1907257 [TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin. Belvedere G; Imperatori L; Damia G; Tagliabue G; Meijer C; de Vries EG; D'Incalci M Eur J Cancer; 1996 Oct; 32A(11):2011-8. PubMed ID: 8943689 [TBL] [Abstract][Full Text] [Related]
28. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813 [TBL] [Abstract][Full Text] [Related]
29. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor. Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890 [TBL] [Abstract][Full Text] [Related]
30. Pretreatment with 5-fluorouracil enhances cytotoxicity and retention of DNA-bound platinum in a cisplatin resistant human ovarian cancer cell line. Tanaka T; Masuda H; Naito M; Tamai H Anticancer Res; 2001; 21(4A):2463-9. PubMed ID: 11724308 [TBL] [Abstract][Full Text] [Related]
31. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Lau DH; Lewis AD; Ehsan MN; Sikic BI Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140 [TBL] [Abstract][Full Text] [Related]
32. Radiation resistance in a melphalan-resistant subline of a rat mammary carcinoma. Lehnert S; Vestergaard J; Batist G; Aloui-Jamali MA Radiat Res; 1994 Aug; 139(2):232-9. PubMed ID: 8052700 [TBL] [Abstract][Full Text] [Related]
33. DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard. Zwelling LA; Michaels S; Schwartz H; Dobson PP; Kohn KW Cancer Res; 1981 Feb; 41(2):640-9. PubMed ID: 7192601 [No Abstract] [Full Text] [Related]
34. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line. Esaki T; Nakano S; Tatsumoto T; Kuroki-Migita M; Mitsugi K; Nakamura M; Niho Y Cancer Res; 1992 Dec; 52(23):6501-6. PubMed ID: 1423296 [TBL] [Abstract][Full Text] [Related]
35. Flow cytometric analysis of DNA damage and repair in the cells resistant to alkylating agents. Frankfurt OS; Seckinger D; Sugarbaker EV Cancer Res; 1990 Aug; 50(15):4453-7. PubMed ID: 2369722 [TBL] [Abstract][Full Text] [Related]
36. Interactions of cis-diamminedichloroplatinum(II) with 1-beta-D-arabinofuranosylcytosine in LoVo colon carcinoma cells. Fram RJ; Robichaud N; Bishov SD; Wilson JM Cancer Res; 1987 Jul; 47(13):3360-5. PubMed ID: 3107809 [TBL] [Abstract][Full Text] [Related]
38. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro. Papadopoulou MV; Ji M; Khan SH; Bloomer WD Oncol Res; 1999; 11(8):345-57. PubMed ID: 10803738 [TBL] [Abstract][Full Text] [Related]
39. Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. Chen G; Waxman DJ Biochem Pharmacol; 1994 Mar; 47(6):1079-87. PubMed ID: 8147907 [TBL] [Abstract][Full Text] [Related]
40. Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines. Mistry P; Loh SY; Kelland LR; Harrap KR Int J Cancer; 1993 Nov; 55(5):848-56. PubMed ID: 8244583 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]